Hims & Hers Health Inc HIMS shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their ...

By Amina Niasse NEW YORK, June 25 (Reuters) - Telehealth provider Hims and Hers Health may get a boost next year from ...

Hims & Hers Health (HIMS) is evolving into a scaled, subscription-driven consumer health platform with strong recurring revenue potential. HIMS faces near-term headwinds from GLP-1 partnership ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Hims and Hers' stock fell over 19% in after-hours trading on Monday ...

CEO Andrew Dudum stated the company's strategy is "expanding reach, deepening engagement and transforming how people experience health care," emphasizing that "scale doesn't just make us bigger, it ...

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. But shares of the company dropped 19% in ...

Hims & Hers Health has spent the past month surprising Wall Street with a 32% rally, all while more than a third of its available shares are held by investors betting the stock will fall. Today, the ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

GLP-1 drugs for weight loss said they planned to drop the drugs in 2027, according to the Business Group on Health (AFP via ) ...